文献速递临床试验与 GCP

围手术期消化道选择性去污染预防食管切除术后严重感染并发症:PERSuaDER 试验研究方案,一项在原发性可切除食管癌患者中开展的多中心随机对照试验

PERi-operative Selective Decontamination of the digestive tract to prevent severe infectious complications after Esophageal Resection: study protocol of the PERSuaDER-trial, a multicenter randomized controlled trial in patients with primary resectable esophageal carcinoma.
PubMed 文献 · Trials · 2025-12-04

PERSuaDER 试验为随机、对照、开放标签、优效性、多中心、实用性、成组序贯试验,拟纳入 854 例原发性可切除食管癌((y)cT1-4a N0-3 M0)并计划行经胸食管切除术的患者,评价围手术期消化道选择性去污染(SDD)能否降低术后肺炎。干预组在标准治疗基础上接受 SDD 预防,SDD 含两性霉素 B 口服混悬液及多黏菌素 E 硫酸盐联合妥布霉素口服溶液,自手术前 3 天起每日吞咽 4 次、持续 1 周,手术当日给 2 剂;对照组仅接受不含 SDD 的标准治疗。

要点

  • PERSuaDER 试验拟纳入 854 例原发性可切除食管癌患者,评估围手术期 SDD 能否降低食管切除术后肺炎。
  • SDD 含两性霉素 B 口服混悬液及多黏菌素 E 硫酸盐联合妥布霉素口服溶液,术前 3 天开始每日 4 次、持续 1 周,手术当日 2 剂。
  • 试验为随机、对照、开放标签、优效性、多中心、实用性、成组序贯设计,将在 30% 和 60% 参与者完成术后 30 天随访后行中期分析。

核心结论

  • 研究假设在食管癌手术标准围手术期治疗中加入 SDD 可降低术后肺炎发生率。
  • 试验还将评估 SDD 对术后(感染性)并发症和生活质量的影响及其成本效果。

研究设计与样本

  • PERSuaDER 试验为随机、对照、开放标签、优效性、多中心、实用性、成组序贯试验。
  • 拟纳入 854 例原发性可切除食管癌((y)cT1-4a N0-3 M0)并计划行经胸食管切除术的患者。
  • 干预组在标准治疗基础上接受 SDD 预防,对照组接受不含 SDD 的标准治疗。
  • 将在 30% 和 60% 参与者完成术后 30 天随访后以及试验完成或终止后进行中期分析。

关键数值与推荐

  • SDD 含两性霉素 B 口服混悬液及多黏菌素 E 硫酸盐联合妥布霉素口服溶液两种口服液。
  • 参与者自手术前 3 天起每日吞咽 SDD 混悬液 4 次、持续 1 周,手术当日给 2 剂。
  • 试验注册于 ClinicalTrials.gov(NCT05865743)和欧洲临床试验信息系统(CTIS)(EU 试验编号:2023-504144-33)。
  • 试验授权日期为 2024 年 3 月 25 日,方案版本 1.1,日期为 2024 年 3 月 3 日。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Esophagectomy is a highly complex surgical procedure, and it is associated with significant morbidity and mortality. The postoperative complication rate is high, with pneumonia being the most common. These are thought to arise from (micro-)aspiration of bacteria residing in the oropharyngeal and gastrointestinal (GI) tract. Selective decontamination of the digestive tract (SDD) is a prophylactic antibiotic strategy aimed at preventing these infections. SDD decolonizes the oropharyngeal and GI tract from pathogenic aerobic gram-negative rods, fungi and yeasts, while anaerobic, protective microbiota are preserved. The PERSuaDER trial aims to evaluate whether perioperative SDD can reduce postoperative pneumonia after esophagectomy. METHODS: The PERSuaDER-trial is a randomized, controlled, open-label, superiority, multicenter, pragmatic, group-sequential trial aiming to include 854 patients with primary resectable esophageal carcinoma ((y)cT1-4a N0-3 M0) scheduled for transthoracic esophagectomy. The intervention group will receive SDD prophylaxis in addition to the standard care regimen. The SDD treatment comprises two oral liquids: an oral suspension containing amphotericin B and an oral solution containing both colistin sulfate and tobramycin. Participants are required to swallow the SDD suspension four times a day for 1 week, starting 3 days prior to the surgical procedure, with two doses on the day of surgery. All other aspects of care are identical to those provided to the control group (standard care without SDD). Participants will be asked to keep a diary and fill out quality of life, medical consumption, and productivity cost questionnaires. Interim analyses will take place after 30% and 60% of the participants have completed follow-up of 30 days after surgery, and after completion or termination of the trial. DISCUSSION: It is hypothesized that the addition of SDD to the standard peri-operative care in esophageal cancer surgery will result in a reduction in the incidence of postoperative pneumonia. Furthermore, the trial will evaluate the impact of SDD on postoperative (infectious) complications and quality of life, and its cost-effectiveness. TRIAL REGISTRATION: The PERSuaDER trial is registered in ClinicalTrials.gov (NCT05865743) and the European Clinical Trials Information System (CTIS) (EU Trial number: 2023-504144-33), Trial authorization date: 25.03.2024, protocol version 1.1, date: 03.03.2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Grootenhuis JGA, Seurs W, Garms LM, et al. PERi-operative Selective Decontamination of the digestive tract to prevent severe infectious complications after Esophageal Resection: study protocol of the PERSuaDER-trial, a multicenter randomized controlled trial in patients with primary resectable esophageal carcinoma. Trials. 2025. PMID: 41345690. doi:10.1186/s13063-025-09311-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。